Table 2. HCV therapies and treatment success.
| Total Population N = 432 |
SVR12 N = 404 |
No SVR12 N = 28 |
|
|---|---|---|---|
| HCV Therapies | N (%) | n (% SVR12) | n (% No SVR12) |
| DAA +RBVa | 70 (16.2%) | 59 (84.3%) | 11 (15.7%) |
| SOFb + RBV | 39 (9.0%) | 32 (82.1%) | 7 (17.9%) |
| PRODc + RBV | 13 (3.0%) | 10 (76.9%) | 3 (23.1%) |
| SOF + PEGd + RBV | 6 (1.4%) | 6 (100.0%) | 0 (0.0%) |
| LDVe-SOF + RBV | 5 (1.2%) | 5 (100.0%) | 0 (0.0%) |
| SMVf + SOF + RBV | 4 (0.9%) | 3 (75.0%) | 1 (25.0%) |
| SOF-VELg + RBV | 2 (0.5%) | 2 (100.0%) | 0 (0.0%) |
| DCVh + SOF + RBV | 1 (0.2%) | 1 (100.0%) | 0 (0.0%) |
| DAA—RBV | 362 (83.8%) | 345 (95.3%) | 17 (4.7%) |
| LDV-SOF | 285 (66.0%) | 272 (95.4%) | 13 (4.6%) |
| SMV + SOF | 29 (6.7%) | 27 (93.1%) | 2 (6.9%) |
| EBR-GZRi | 17 (3.9%) | 16 (94.1%) | 1 (5.9%) |
| DCV + SOF | 15 (3.5%) | 15 (100.0%) | 0 (0.0%) |
| SOF + VEL | 11 (2.5%) | 10 (90.9%) | 1 (9.1%) |
| PROD | 5 (1.2%) | 5 (100.0%) | 0 (0.0%) |
a RBV = ribavirin.
b SOF = sofosbuvir.
c PROD = paritaprevir/ritonavir-ombitasvir and dasabuvir.
d PEG = peginterferon.
e LDV = ledipasvir.
f SMV = simeprevir.
g VEL = velpatasvir.
h DCV = daclatasvir.
i EBR-GZR = elbasvir-grazoprevir.